Molina Healthcare Reports Third Quarter 2026 Financial Results

Molina Healthcare reported Q3 2026 GAAP income per diluted share of $0.73 and adjusted income per diluted share of $0.89. Total revenue was $11.082B, down from $11.477B a year earlier, while premium revenue was $10.457B versus $10.841B. The excerpt provides no EPS comparisons or outlook.

Analysis

The disclosed revenue and EPS figures alone do not establish whether the quarter is a fundamental miss: expectations, medical-cost performance, membership mix, and full-year guidance are absent. The key mechanism to test is whether lower premium revenue reflects planned membership runoff or weaker retention/pricing; the former can be manageable, while the latter would raise concern that rate setting is not keeping pace with acuity and medical costs. The GAAP-to-adjusted EPS gap also makes the nature and recurrence of adjustments important before treating adjusted earnings power as durable.

Near term, the earnings call and any guidance change matter more than the top-line decline in isolation. Over 1–3 months, watch medical care ratio, Medicaid contract repricing, membership/acuity, and state-level rate updates. Over 6–18 months, persistently inadequate rates could pressure margins and make Molina less attractive versus more diversified managed-care companies; conversely, stable margins alongside planned enrollment contraction would weaken the bearish case. A broad sector move could obscure company-specific execution, so compare Molina’s margin and guidance trajectory with peers such as Centene, Elevance Health, and UnitedHealth Group. The contrarian risk is overreacting to lower revenue without evidence of deteriorating unit economics.

Key Decisions for Investors

• Do not initiate a directional position from this excerpt alone. Before trading, verify consensus versus reported results, full-year EPS guidance, medical care ratio, enrollment and acuity trends, and the drivers of the GAAP/adjusted earnings difference.
• Event-driven posture: keep Molina on an underweight watchlist rather than shorting immediately; consider a relative-value underweight versus diversified managed-care peers only if the call confirms margin pressure or a guidance reduction.
• Falsify the cautious thesis if management maintains guidance and reports stable or improving medical-cost performance, with membership changes explained by deliberate portfolio or enrollment actions rather than adverse retention or pricing.
• Escalate concern if guidance is cut or medical care costs outpace rate updates; reassess after state rate notices and the next quarterly enrollment and margin disclosures.